Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 6 days ago

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.

Role of genomics in colorectal cancers

Dr Joslyn Ngu
04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Colorectal cancer is not a single disease, but a set of molecularly distinctive diseases with the same clinical presentation, said Associate Professor Ho Gwo Fuang, clinical oncologist at the University Malaya Medical Centre. By stratifying patients into clinically relevant molecular subtypes, treatment can be more personalized. Genomics advancements has allowed for better risk stratification of early stage disease and these are carried out by gene signature profiling tools such as ColoPrint, Ocotype Dx and ColDx (now called GeneFx Colon).

There are four consensus molecular subtypes of CRCs: CSM1 to 4. CSM1 tumours are more commonly found in the proximal colon. Generally, they are poorly differentiated, of mucinous subtype and have dense lymphocytic infiltration. This indicates strong antitumoural immune response which makes good targets for immune checkpoint inhibitors. CSM 2 to 4 are usually located towards the distal part of the colon and rectum. CSM 2 and 3 tumours are immune-ignorant and CSM 4 tumours are immune-tolerant. The most common mutation pathways in CRC include APC, RAS and Wnt pathways. The last occurs in 93 percent of patients, he said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 6 days ago

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.